Receive The Newest Study Notifications

AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the company has successfully microencapsulated cannabinoids into its patented chewing gum delivery mechanism for use in the...

Debiopharm International SA (Debiopharm – www.debiopharm.com/debiopharm-international/), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate its afabicin (Debio 1450) for the...

PRA Health Sciences and the non-profit Center for Information and Study on Clinical Research Participation (CISCRP) are pleased to announce that they are collaborating to prepare and deliver Trial Results Summaries to study volunteers. A key focus for PRA is to...

Results from a pioneering clinical trials programme that delivered an experimental treatment directly to the brain offer hope that it may be possible to restore the cells damaged in Parkinson's. The multimillion-pound study, funded by Parkinson's UK with support from...

Veritas Pharma Puerto Rico LLC, a wholly owned subsidiary of Veritas Pharma, Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), today announced the dosing of the first adult volunteer in its clinical trial of their lead cannabis product (“CTL-X”) for the...

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ″Company″ or ″Lexaria″), a drug delivery platform innovator, is pleased to announce additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled,...

The drug has been specifically developed for the nonalcoholic fatty liver disease (NASH) The clinical trial is expected to report by the third quarter of 2019 Boehringer Ingelheim (Boehringer), a renowned German pharmaceutical firm, has reportedly announced that it...

Increasing Awareness, Dispelling Myths, and Helping Patients Find the Right Trials The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today launches its nationwide “Fight Back Give Back” campaign to highlight the importance of...

Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC Davis Health (“UC Davis”) located in Sacramento, California to be the clinical trial site for the Company’s Phase II...

TAT International Congress 2019 -- Paris, France -- Feb. 25-27, 2019 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumour types receive...

Phoenix Tissue Repair, Inc., a biotechnology company focused on developing transformational disease-modifying treatments for dystrophic epidermolysis bullosa (DEB), today announced that the first patient has been dosed in the Phase 1/2, first in-human trial of PTR-01...

DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association Viaskin Peanut is the first epicutaneous immunotherapy (EPIT) in development...

Data show that PVX108, a peptide-based immunotherapy, has a highly favorable safety profile for the treatment of peanut allergy MELBOURNE, Australia, Feb. 24, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage biotechnology company focused on developing a...

Stage 1 of the Phase 2 CRIOM study evaluates the maximum tolerable dose of EC-18 which will be used in Stage 2 of the study. Representative Image Enzychem Lifesciences, a global biopharmaceutical company headquartered in Seoul, Korea which is dedicated to developing...

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has initiated a Phase 1...

On January 23, 2019, the European Data Protection Board (“EDPB”) issued an interesting opinion about personal data processed in relation to clinical trials. The main role of the EDPB – which succeeded the Article 29 Working Party – is to contribute to the consistent...

Veritas Pharma Puerto Rico LLC, a wholly owned subsidiary of Veritas Pharma, Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), today announced the dosing of the first adult volunteer in its clinical trial of their lead cannabis product (“CTL-X”) for the...

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ″Company″ or ″Lexaria″), a drug delivery platform innovator, is pleased to announce additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled,...

First commercial program under Bavarian Nordic and Janssen Vaccines & Prevention B.V. collaboration advancing into clinical trials -- A therapeutic vaccine may represent a novel approach for early treatment and interception of HPV-induced cancers COPENHAGEN,...

Phoenix Tissue Repair, Inc., a biotechnology company focused on developing transformational disease-modifying treatments for dystrophic epidermolysis bullosa (DEB), today announced that the first patient has been dosed in the Phase 1/2, first in-human trial of PTR-01...